Franco Maggiolo

4.7k total citations
114 papers, 2.5k citations indexed

About

Franco Maggiolo is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Franco Maggiolo has authored 114 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 102 papers in Infectious Diseases, 83 papers in Virology and 21 papers in Emergency Medicine. Recurrent topics in Franco Maggiolo's work include HIV/AIDS drug development and treatment (88 papers), HIV Research and Treatment (83 papers) and HIV/AIDS Research and Interventions (65 papers). Franco Maggiolo is often cited by papers focused on HIV/AIDS drug development and treatment (88 papers), HIV Research and Treatment (83 papers) and HIV/AIDS Research and Interventions (65 papers). Franco Maggiolo collaborates with scholars based in Italy, United States and United Kingdom. Franco Maggiolo's co-authors include Diego Ripamonti, Claudio Arici, Fredy Suter, Annapaola Callegaro, Fredy Suter, Monica Airoldi, Giampaolo Quinzan, Laura Ravasio, Daniela Valenti and Annapaola Callegaro and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Clinical Infectious Diseases.

In The Last Decade

Franco Maggiolo

108 papers receiving 2.4k citations

Peers

Countries citing papers authored by Franco Maggiolo

Since Specialization

Citations

This map shows the geographic impact of Franco Maggiolo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Franco Maggiolo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Franco Maggiolo more than expected).

Fields of papers citing papers by Franco Maggiolo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Franco Maggiolo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Franco Maggiolo. The network helps show where Franco Maggiolo may publish in the future.

Co-authorship network of co-authors of Franco Maggiolo

This figure shows the co-authorship network connecting the top 25 collaborators of Franco Maggiolo. A scholar is included among the top collaborators of Franco Maggiolo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Franco Maggiolo. Franco Maggiolo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors	BMJ Open	Laura Galli, Roberta Gagliardini et al.	6
2	Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry	International Journal of Antimicrobial Agents	Francesco Saladini, Franco Maggiolo et al.	4
3	Correlates of Treatment and Disease Burden in People Living with HIV (PLHIV) in Italy	Journal of Clinical Medicine	Antonella Cingolani, Alessandro Tavelli et al.	2
4	Awareness and perception of accuracy of the Undetectable=Untransmittable message (U=U) in Italy: results from a survey among PLWHA, infectious-diseases physicians and people having unprotected sex	AIDS Care	Antonella Cingolani, Alessandro Tavelli et al.	4
5	Real world efficacy of dolutegravir plus lamivudine in people living with HIV with undetectable viral load after previous failures	Journal of Global Antimicrobial Resistance	Roberta Gagliardini, Patrizia Lorenzini et al.	5
6	Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients	BMC Infectious Diseases	Franco Maggiolo, Roberto Gulminetti et al.	8
7	In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patients	Journal of Antimicrobial Chemotherapy	Francesco Saladini, Franco Maggiolo et al.	11
8	Marked decrease in acquired resistance to antiretrovirals in latest years in Italy	Clinical Microbiology and Infection	Alessia Lai, Marco Franzetti et al.	4
9	Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial	The Lancet HIV	Hans‐Jürgen Stellbrink, José Ramón Arribas et al.	99
10	Evolution of major non‐HIV‐related comorbidities in HIV‐infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014	HIV Medicine	Antonella d’Arminio Monforte, Helena Díaz-Cuervo et al.	23
11	Post-treatment controllers after treatment interruption in chronically HIV-infected patients	AIDS	Franco Maggiolo, Elisa Di Filippo et al.	17
12	Reduced adherence to antiretroviral therapy is associated with residual low-level viremia	PubMed	Franco Maggiolo, Elisa Di Filippo et al.	25
13	Switching from an EFV-Based STR to a RPV-Based STR is Effective, Safe and Improves HIV Patients Health Status	Value in Health	Elisa Di Filippo, Daniela Valenti et al.	1
14	Migration patterns of HIV-1 subtype B virus in Northern Italy.	PubMed	Alessandra Lo Presti, Massimo Ciccozzi et al.	6
15	A Randomized Phase 3 Study Comparing Once-Daily Elvitegravir With Twice-Daily Raltegravir in Treatment-Experienced Subjects With HIV-1 infection	JAIDS Journal of Acquired Immune Deficiency Syndromes	Richard Elion, Jean‐Michel Molina et al.	33
16	Effect of Adherence to HAART on Virologic Outcome and on the Selection of Resistance-Conferring Mutations in NNRTI- or PI-Treated Patients	HIV Clinical Trials	Franco Maggiolo, Monica Airoldi et al.	129
17	Reasons for discontinuation of nevirapine-containing HAART: results from an unselected population of a large clinical cohort	Journal of Antimicrobial Chemotherapy	Franco Maggiolo, Claudio Arici et al.	13
18	Resistance Costs and Future Drug Options of Antiretroviral Therapies: Analysis of the Role of NRTIs, NNRTIs, and PIs in a Large Clinical Cohort	HIV Clinical Trials	Franco Maggiolo, Diego Ripamonti et al.	7
19	Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER Cohort	Journal of Antimicrobial Chemotherapy	Carlo Torti, Franco Maggiolo et al.	29
20	Efavirenz, Nelfinavir, and Stavudine Rescue Combination Therapy in HIV-1–Positive Patients Heavily Pretreated With Nucleoside Analogues and Protease Inhibitors	JAIDS Journal of Acquired Immune Deficiency Syndromes	Elena Seminari, Franco Maggiolo et al.	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact